We Build Hyper-Generics.
Better | Faster | Cheaper | Risk-minimized
We Build Hyper-Generics.
better. faster. cheaper. risk-minimized.
Why we do it - our mission
Pharmaceuticals are essential for health and cure.
They can provide high quality of live and make the difference in mortality or support patients even in palliative therapy.
That are recognized as key medicinal products in their therapeutic area.
With a well-documented safety and efficiency profile.
Better than the original market leader.
Affordable for all income classes.
We believe that our products can make a significant difference in quality of life and patient safety.
And we can offer these innovative therapies for a price that makes them accessible for all who will need them.
How we do it
Re-formulating pharmaceuticals.
Based on world-leading nano-technology.
Most of modern drugs are highly insoluble when taken as a tablet. In practical terms: they are soluble as marble when taken as a tablet.
This requires high dosage to achieve a therapeutic effect at all. But it also requires fastening before or after taking it.
This we can overcome by the nano-technology we use.
- Lower dosage for same therapeutics effect
- No interaction with food
- Lower interpatient variability
Beside this, we can prove better patient outcome or even modify the original pharmaceutical in a way that it has complete new therapeutic effects.
The Outcome: Hyper-Generics
Taking approved pharmaceutical products and make them better than the original market leader, this is the InnovatHealth way to “HyperGenerics.” A new class of medicinal products. We develop HyperGenerics, achieve Marketing Authorization and sell those rights with access to the technology to pharmaceutical companies.
What we do
For the patient
Patients must relay on safe and efficient products. We will top this with more patient comfort by dose reduction and independence of food intake. No fastening or no fat enriched meals to achieve a reliable uptake and bioavailability. This way it is our objective to increase quality of life for the patient.
For the healthcare system
For our customers
The pharmaceutical market is highly competitive when market exclusivity has fallen for a product. Our customers do not have to compete on price level, they can compete and gain market share by better product characteristics. Sometimes it is just a small difference, but it strong enough to achieve differentiation and a competitive advantage.
About InnovatHealth
InnovatHealth was started in 2019 by founders with a broad and different professional background in Munich.
Each is an expert on world class level in his dedicated field.
Together they are the synergy of technology, entrepreneurship and pharmaceutical development
Dipl. Wi.Ing.
Matthias Ehrlich
CEO
Executive in Technology and IT Industry,
former Chairman of 1&1 Internet AG
(Co-) Founder
of technology-driven companies in diversified segments
10 years experience
in financing Technology companies
Matthias has served more than 25 years in technology industries and has championed a number of assets as well in the fintech industry. With his vast experience in the IT sector, he has helped several world class companies to achieve outstanding results. He served as Chairman and Board member of 1&1/United Internet AG; Web.de, Informia AG and several others. He is a (Co-) Founder of multiple technology-driven companies in diversified segments. He serves on several boards in the IT.
Dr. Frank Perabo
USA
Executive Vice President R&D
former Essa Pharmaceuticals, Houston, TX (USA)
Responsible for registration of XTANDI, a global blockbuster drug with p.a. sales $5 Bn
20 years experience
in Biotech and Pharma drug development
Frank has more than 20 years of business acumen in Pharma and Biotech. He served for Biotech companies in the US as CEO and held positions of substantial responsibilities, such as CMO & Executive VP Clinical Development for ESSA Pharmaceuticals, Houston. He served on the board as Executive Director Medical Science Astellas Pharmaceuticals for more than 7 years, where he supervised the development and launch of blockbuster drug XTANDI®. He served as Scientific Director at Oncology World GmbH.
Dipl. Wi.Ing.
Matthias Ehrlich
CEO
Dr. Frank Perabo
USA
Executive in Technology and IT Industry,
former Chairman of 1&1 Internet AG
(Co-) Founder
of technology-driven companies in diversified segments
10 years experience
in financing Technology companies
Matthias has served more than 25 years in technology industries and has championed a number of assets as well in the fintech industry. With his vast experience in the IT sector, he has helped several world class companies to achieve outstanding results. He served as Chairman and Board member of 1&1/United Internet AG; Web.de, Informia AG and several others. He is a (Co-) Founder of multiple technology-driven companies in diversified segments. He serves on several boards in the IT.
Executive Vice President R&D
former Essa Pharmaceuticals, Houston, TX (USA)
Responsible for registration of XTANDI, a global blockbuster drug with p.a. sales $5 Bn
20 years experience
in Biotech and Pharma drug development
Frank has more than 20 years of business acumen in Pharma and Biotech. He served for Biotech companies in the US as CEO and held positions of substantial responsibilities, such as CMO & Executive VP Clinical Development for ESSA Pharmaceuticals, Houston. He served on the board as Executive Director Medical Science Astellas Pharmaceuticals for more than 7 years, where he supervised the development and launch of blockbuster drug XTANDI®. He served as Scientific Director at Oncology World GmbH.
Dr. K.M.
COO + Europa
Managing Director
Global Pharma company
20 years experience
in Pharma and Operations
Klaus has more than 20 years of leadership experience in the global pharm business, among which he had several global headquarter functions in drug safety and medical sciences. Under his leadership several highly important clinical research programs in complex molecules were conducted in different therapeutic areas. He was in charge for the launches of a new and first-in-class medicinal product. The buildup and development of a completely new pharma markets segment and product portfolio was managed by him with global annual sales of 3 bn USD. He was supervising the cGMP implementation in 18 production units and has led international marketing & sales teams reporting to him.
Jan Trinemeier
Finance & Operationals
Executive Manager Operation
Formerly working for m&a and strategic consulting company and as resident manager
Responsible for b2b sales process built up for a leading German streaming provider
8 years experience in various innovative growth companies
Jan has 8 years experience in developing innovative business models into market-ready companies and subsequently guiding the scaling process, mainly focusing on financing and controlling.
Dr. K.M.
COO + Europa
Jan Trinemeier
Finance & Operationals
Managing Director
Global Pharma company
20 years experience
in Pharma and Operations
Klaus has more than 20 years of leadership experience in the global pharm business, among which he had several global headquarter functions in drug safety and medical sciences. Under his leadership several highly important clinical research programs in complex molecules were conducted in different therapeutic areas. He was in charge for the launches of a new and first-in-class medicinal product. The buildup and development of a completely new pharma markets segment and product portfolio was managed by him with global annual sales of 3 bn USD. He was supervising the cGMP implementation in 18 production units and has led international marketing & sales teams reporting to him.
Executive Manager Operation
Formerly working for m&a and strategic consulting company and as resident manager
Responsible for b2b sales process built up for a leading German streaming provider
8 years experience in various innovative growth companies
Jan has 8 years experience in developing innovative business models into market-ready companies and subsequently guiding the scaling process, mainly focusing on financing and controlling.